200 likes | 229 Views
EMP Technical Briefing Seminar Good Governance for Medicines programme EMRO Regional Perspective November 2009, Geneva, Switzerland. Essential Medicines and Pharmaceutical Policies Unit November 2009 – Good Governance for Medicines 1. WHO Eastern Mediterranean Region 22 countries.
E N D
EMP Technical Briefing Seminar Good Governance for Medicines programme EMRO Regional Perspective November 2009, Geneva, Switzerland Essential Medicines and Pharmaceutical Policies Unit November 2009 – Good Governance for Medicines 1
Observations • Global supplier of crude oil and natural gas • Suffers from numerous wars and emergency situations • Comprises a mix of richest and poorest countries
Medicines • 40% of total health expenditures • Up to 30% of MOH budgets • Out-of-pocket expenditure high (up to 74%)
Diversity in medicines situation: examples • Lower middle income country (Pakistan) with large number of medicines manufacturers • High income country (Qatar) no medicines producers • Lower middle income country (Jordan) has FDA with over 400 staff • Upper middle income country (Libya) with limited regulatory capacity
GGM Progress Other EOI
Transparency assessments Jordan GGM Framework Lebanon GGM Framework
Common strengths • Political commitment to increasing access to medicines • Presence of medicines laws in all countries • Active technical committees in various functions • Registration systems • Essential medicines lists • Qualified human resources
Common gaps • Policy on conflict of interest • Declaration • Management • Sanctions on violation • Written guidelines on membership in committees (including rotation policies) • Standard operating procedures (especially for decision making process) • Public availability of information
Common gaps (cont’d) • Control of medicines promotion • Direct to consumer • Medical professionals • Civil society engagement • Presence of suitable codes of conduct • Civil service • Professional association • Manufacturers association • Socialization of codes of conduct
Common gaps (cont’d) • Sanctions on reprehensible acts • Enforcement mechanisms • Guidelines on interaction between public officials and private sector • Independent complaints mechanism • Protection of whistle blowers • Limited resources
Complimentarity with other programmes • Medicines Transparency Alliance (MeTA) • MRA support • Health system strengthening • Country Cooperation Strategies
EMRO GGM country support • New and experimental field • Not limited to developing countries • Is not isolated from overall governance system • Encourages sharing views and experiences across countries • Growing roster of human resources • Technical documents in Arabic • Stakeholder involvement from outside the medicines sector • Sum of WHO technical support ≈ sum of lessons learned in countries
More information • On EMR medicines situation • www.emro.who.int/emp • On GGM programme • www.who.int/medicines/ggm
Thank you وشكراً